Denmark · Delayed Price · Currency is DKK Zealand Pharma Statistics
Total Valuation
Zealand Pharma has a market cap or net worth of DKK 16.21 billion. The enterprise value is 2.17 billion.
| Market Cap | 16.21B |
| Enterprise Value | 2.17B |
Important Dates
The next confirmed earnings date is Thursday, November 12, 2026.
| Earnings Date | Nov 12, 2026 |
| Ex-Dividend Date | n/a |
Share Statistics
Zealand Pharma has 68.11 million shares outstanding. The number of shares has decreased by -0.27% in one year.
| Current Share Class | 68.11M |
| Shares Outstanding | 68.11M |
| Shares Change (YoY) | -0.27% |
| Shares Change (QoQ) | +0.24% |
| Owned by Insiders (%) | 0.26% |
| Owned by Institutions (%) | 25.80% |
| Float | 58.31M |
Valuation Ratios
The trailing PE ratio is 6.18.
| PE Ratio | 6.18 |
| Forward PE | n/a |
| PS Ratio | 3.49 |
| PB Ratio | 0.90 |
| P/TBV Ratio | 0.94 |
| P/FCF Ratio | n/a |
| P/OCF Ratio | n/a |
| PEG Ratio | n/a |
Enterprise Valuation
| EV / Earnings | 0.79 |
| EV / Sales | 0.47 |
| EV / EBITDA | 0.93 |
| EV / EBIT | 0.94 |
| EV / FCF | n/a |
Financial Position
The company has a current ratio of 13.98, with a Debt / Equity ratio of 0.02.
| Current Ratio | 13.98 |
| Quick Ratio | 13.76 |
| Debt / Equity | 0.02 |
| Debt / EBITDA | 0.18 |
| Debt / FCF | -0.23 |
| Interest Coverage | 85.26 |
Financial Efficiency
Return on equity (ROE) is 16.31% and return on invested capital (ROIC) is 101.93%.
| Return on Equity (ROE) | 16.31% |
| Return on Assets (ROA) | 7.81% |
| Return on Invested Capital (ROIC) | 101.93% |
| Return on Capital Employed (ROCE) | 12.52% |
| Weighted Average Cost of Capital (WACC) | 7.57% |
| Revenue Per Employee | 8.03M |
| Profits Per Employee | 4.74M |
| Employee Count | 578 |
| Asset Turnover | 0.25 |
| Inventory Turnover | n/a |
Taxes
In the past 12 months, Zealand Pharma has paid 99.06 million in taxes.
| Income Tax | 99.06M |
| Effective Tax Rate | 3.49% |
Stock Price Statistics
The stock price has decreased by -53.33% in the last 52 weeks. The beta is 0.61, so Zealand Pharma's price volatility has been lower than the market average.
| Beta (5Y) | 0.61 |
| 52-Week Price Change | -53.33% |
| 50-Day Moving Average | 295.02 |
| 200-Day Moving Average | 325.99 |
| Relative Strength Index (RSI) | 27.84 |
| Average Volume (20 Days) | 412,998 |
Short Selling Information
| Short Interest | n/a |
| Short Previous Month | n/a |
| Short % of Shares Out | n/a |
| Short % of Float | n/a |
| Short Ratio (days to cover) | n/a |
Income Statement
In the last 12 months, Zealand Pharma had revenue of DKK 4.64 billion and earned 2.74 billion in profits. Earnings per share was 38.53.
| Revenue | 4.64B |
| Gross Profit | 4.64B |
| Operating Income | 2.31B |
| Pretax Income | 2.84B |
| Net Income | 2.74B |
| EBITDA | 2.32B |
| EBIT | 2.31B |
| Earnings Per Share (EPS) | 38.53 |
Balance Sheet
The company has 14.46 billion in cash and 411.00 million in debt, with a net cash position of 14.05 billion or 206.21 per share.
| Cash & Cash Equivalents | 14.46B |
| Total Debt | 411.00M |
| Net Cash | 14.05B |
| Net Cash Per Share | 206.21 |
| Equity (Book Value) | 18.00B |
| Book Value Per Share | 259.39 |
| Working Capital | 17.35B |
Cash Flow
In the last 12 months, operating cash flow was -1.75 billion and capital expenditures -43.37 million, giving a free cash flow of -1.80 billion.
| Operating Cash Flow | -1.75B |
| Capital Expenditures | -43.37M |
| Depreciation & Amortization | 16.95M |
| Net Borrowing | -28.16M |
| Free Cash Flow | -1.80B |
| FCF Per Share | -26.37 |
Margins
Gross margin is 100.00%, with operating and profit margins of 49.68% and 59.02%.
| Gross Margin | 100.00% |
| Operating Margin | 49.68% |
| Pretax Margin | 61.16% |
| Profit Margin | 59.02% |
| EBITDA Margin | 50.05% |
| EBIT Margin | 49.68% |
| FCF Margin | n/a |
Dividends & Yields
Zealand Pharma does not appear to pay any dividends at this time.
| Dividend Per Share | n/a |
| Dividend Yield | n/a |
| Dividend Growth (YoY) | n/a |
| Years of Dividend Growth | n/a |
| Payout Ratio | n/a |
| FCF Payout Ratio | n/a |
| Buyback Yield | 0.27% |
| Shareholder Yield | 0.27% |
| Earnings Yield | 16.91% |
| FCF Yield | -11.08% |
Fair Value
There are several formulas that can be used to estimate the intrinsic value of a stock.
| Lynch Fair Value | n/a |
| Lynch Upside | n/a |
| Graham Number | |
| Graham Upside |
Analyst Forecast
The average price target for Zealand Pharma is 408.36, which is 71.58% higher than the current price. The consensus rating is "Buy".
| Price Target | 408.36 |
| Price Target Difference | 71.58% |
| Analyst Consensus | Buy |
| Analyst Count | 16 |
| Revenue Growth Forecast (3Y) | -41.95% |
| EPS Growth Forecast (3Y) | n/a |
Stock Splits
This stock does not have any record of stock splits.
| Last Split Date | n/a |
| Split Type | n/a |
| Split Ratio | n/a |
Scores
Zealand Pharma has an Altman Z-Score of 11.27 and a Piotroski F-Score of 2.
| Altman Z-Score | 11.27 |
| Piotroski F-Score | 2 |